These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8100159)

  • 1. Preliminary studies about novel strategies to reverse chemoresistance to adriamycin regarding glutathione metabolism, peroxisomal and extraperoxisomal hydroperoxide and valproic acid metabolic pathways.
    Vamecq J; Vallée L; Fontaine M; Nuyts JP; Lambert D; Poupaert J
    Biol Cell; 1993; 77(1):17-26. PubMed ID: 8100159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of various chemosensitizers on chemoresistance to adriamycin in MIP-101 cell line, a colon carcinoma cell line: analysis of glutathione and related enzymes.
    Mestdagh N; Morier-Teissier E; Hénichart JP
    Anticancer Drugs; 1993 Dec; 4(6):641-50. PubMed ID: 7905301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines.
    Lai GM; Moscow JA; Alvarez MG; Fojo AT; Bates SE
    Int J Cancer; 1991 Nov; 49(5):688-95. PubMed ID: 1682279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CoA esters of valproic acid and related metabolites are oxidized in peroxisomes through a pathway distinct from peroxisomal fatty and bile acyl-CoA beta-oxidation.
    Vamecq J; Vallee L; Fontaine M; Lambert D; Poupaert J; Nuyts JP
    FEBS Lett; 1993 May; 322(2):95-100. PubMed ID: 8482393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of detoxifying systems in resistance of tumor cells to cisplatin and adriamycin.
    Meijer C; Mulder NH; de Vries EG
    Cancer Treat Rev; 1990 Dec; 17(4):389-407. PubMed ID: 1982706
    [No Abstract]   [Full Text] [Related]  

  • 6. Peroxisomal beta-oxidation and sodium valproate.
    Van den Branden C; Roels F
    Biochem Pharmacol; 1985 Jun; 34(12):2147-9. PubMed ID: 3924057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between peroxisome-proliferating sulfur-substituted fatty acid analogs, hepatic lipid peroxidation and hydrogen peroxide metabolism.
    Demoz A; Svardal A; Berge RK
    Biochem Pharmacol; 1993 Jan; 45(1):257-9. PubMed ID: 8424818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P-glycoprotein and alterations in the glutathione/glutathione-peroxidase cycle underlie doxorubicin resistance in HL-60-R, a subclone of the HL-60 human leukemia cell line.
    Raghu G; Pierre-Jerome M; Dordal MS; Simonian P; Bauer KD; Winter JN
    Int J Cancer; 1993 Mar; 53(5):804-11. PubMed ID: 8095491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous tumor necrosis factor functions as a resistant factor against adriamycin.
    Maeda M; Watanabe N; Okamoto T; Tsuji N; Niitsu Y
    Int J Cancer; 1994 Aug; 58(3):376-9. PubMed ID: 7914182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin and multidrug resistance.
    Kruh GD; Goldstein LJ
    Curr Opin Oncol; 1993 Nov; 5(6):1029-34. PubMed ID: 7905750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of doxorubicin-resistance in sarcoma 180 tumor cells by inhibition of different resistance mechanisms.
    Efferth T; Volm M
    Cancer Lett; 1993 Jul; 70(3):197-202. PubMed ID: 8102593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of the mechanism of resistance to Adriamycin in vivo. Glutathione metabolism, P-glycoprotein expression, and drug transport.
    Lee FY; Sciandra J; Siemann DW
    Biochem Pharmacol; 1989 Nov; 38(21):3697-705. PubMed ID: 2574574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular signalling: the role of the peroxisome.
    Masters CJ
    Cell Signal; 1996 Mar; 8(3):197-208. PubMed ID: 8736704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-competitive inhibition of P-glycoprotein-associated efflux of THP-adriamycin by verapamil in living K562 leukemia cells.
    Pereira E; Borrel MN; Fiallo M; Garnier-Suillerot A
    Biochim Biophys Acta; 1994 Jan; 1225(2):209-16. PubMed ID: 7904185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of hypolipidemic peroxisome proliferator administration on hepatic hydrogen peroxide metabolism in rats.
    Tamura H; Iida T; Watanabe T; Suga T
    Carcinogenesis; 1990 Mar; 11(3):445-50. PubMed ID: 2311188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential oxygen radical susceptibility of adriamycin-sensitive and -resistant MCF-7 human breast tumor cells.
    Mimnaugh EG; Dusre L; Atwell J; Myers CE
    Cancer Res; 1989 Jan; 49(1):8-15. PubMed ID: 2535695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of multidrug resistance in cancer cells.
    Wigler PW
    J Natl Cancer Inst; 1994 Jan; 86(2):148-50. PubMed ID: 7903703
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of prolonged administration of perfluorooctanoic acid on hepatic activities of enzymes which detoxify peroxide and xenobiotic in the rat.
    Kawashima Y; Suzuki S; Kozuka H; Sato M; Suzuki Y
    Toxicology; 1994 Nov; 93(2-3):85-97. PubMed ID: 7974521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferation and resistance to hydrogen peroxide in rat hepatocytes: is development of resistance an adaptation to cytotoxicity?
    Garberg P; Stenius U; Nilsson K; Högberg J
    Carcinogenesis; 1992 Oct; 13(10):1751-8. PubMed ID: 1423834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro steady-state levels of hydrogen peroxide after exposure of male F344 rats and female B6C3F1 mice to hepatic peroxisome proliferators.
    Tomaszewski KE; Agarwal DK; Melnick RL
    Carcinogenesis; 1986 Nov; 7(11):1871-6. PubMed ID: 3769136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.